Warren Buffett has been on a selling spree
Through Berkshire Hathaway…Warren Buffett recently dumped $800 million of Apple stock…

And bought this instead!

He’s now moved $3.8 BILLION in a tiny niche of the tech sector billionaires are flocking to…
Click to see what Buffett knows

RCUS Insider Trading (Arcus Biosciences)

Insider Ownership Percentage: 19.71%
Insider Buying (Last 12 Months): $220,461,794.00
Insider Selling (Last 12 Months): $66,367.95

Arcus Biosciences Insider Trading History Chart

Arcus Biosciences Share Price & Price History

$35.33
▲ +2.05 (6.16%)
As of 02/24/2021 01:00 AM ET
Days: 30 | 90 | 365
Buy This Ticker Now: Projected To Jump 1,530%
With experts projecting gains as high as 1,530% by the end of this year…

Forbes has already confirmed that when all is said and done, "a new class of millionaires may emerge."
Click here and get the ticker… no strings attached

Arcus Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2021Gilead Sciences IncMajor ShareholderBuy5,650,000$39.00$220,350,000.0013,913,029  
12/16/2020William GrossmanInsiderSell2,117$31.35$66,367.95  
9/9/2020Robert C Goeltz IICFOBuy5,000$21.57$107,850.005,000  
7/31/2020William GrossmanInsiderBuy200$19.72$3,944.00500  
6/28/2019Juan C JaenPresidentBuy15,000$7.59$113,850.00  
6/12/2019Kathryn E FalbergDirectorBuy20,000$8.20$164,000.00  
6/10/2019Kathryn E FalbergDirectorBuy32,065$8.07$258,764.55  
6/6/2019Terry J RosenCEOBuy21,738$7.93$172,382.34  
6/4/2019Terry J RosenCEOBuy41,540$7.91$328,581.40  
6/3/2019Juan C JaenPresidentBuy10,000$8.25$82,500.00  
11/13/2018Juan C JaenPresidentBuy10,000$11.80$118,000.00  
8/28/2018Terry J RosenCEOBuy18,607$15.07$280,407.49  
8/24/2018Terry J RosenCEOBuy9,289$13.45$124,937.05  
8/21/2018Terry J RosenCEOBuy8,891$13.24$117,716.84  
8/16/2018Terry J RosenCEOBuy28,401$12.64$358,988.64  
8/13/2018Juan C JaenPresidentBuy10,000$11.88$118,800.00  
8/13/2018Terry J RosenCEOBuy9,929$11.87$117,857.23  
3/19/2018Kathryn E FalbergDirectorBuy30,000$15.00$450,000.00  
3/19/2018Terry J RosenCEOBuy66,666$15.00$999,990.00  
See Full Table

SEC Filings (Institutional Ownership Changes) for Arcus Biosciences (NYSE:RCUS)

60.56% of Arcus Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Arcus Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
2/24/2021Bank Julius Baer & Co. Ltd Zurich14,753$0.38M0.0%-43.1%0.023%
2/23/2021Principal Financial Group Inc.24,080$0.63M0.0%N/A0.037%
2/19/2021JPMorgan Chase & Co.497,142$12.91M0.0%+13.0%0.766%
2/17/2021Jane Street Group LLC8,803$0.23M0.0%-71.9%0.014%
2/16/2021Squarepoint Ops LLC83,448$2.17M0.0%-27.5%0.129%
2/16/2021Baker BROS. Advisors LP72,709$1.89M0.0%-37.0%0.112%
2/16/2021Tudor Investment Corp Et Al35,557$0.92M0.0%N/A0.055%
2/16/2021Nuveen Asset Management LLC204,789$5.32M0.0%-5.3%0.315%
2/16/2021Price T Rowe Associates Inc. MD21,244$0.55M0.0%+86.3%0.033%
2/16/2021Virginia Retirement Systems ET AL9,200$0.24M0.0%N/A0.014%
2/16/2021Engineers Gate Manager LP14,110$0.37M0.0%-59.4%0.022%
2/16/2021Prelude Capital Management LLC17,221$0.45M0.0%N/A0.027%
2/16/2021ExodusPoint Capital Management LP8,390$0.22M0.0%N/A0.013%
2/16/2021Charles Schwab Investment Management Inc.287,080$7.45M0.0%+1.5%0.442%
2/13/2021American International Group Inc.24,502$0.64M0.0%-2.8%0.038%
2/12/2021The Manufacturers Life Insurance Company 25,369$0.66M0.0%+6.4%0.039%
2/12/2021Credit Suisse AG64,557$1.68M0.0%-37.1%0.099%
2/12/2021Vontobel Holding Ltd.10,000$0.41M0.0%N/A0.015%
2/12/2021Virtus ETF Advisers LLC9,188$0.24M0.1%-17.0%0.014%
2/12/2021Personal Capital Advisors Corp9,395$0.24M0.0%N/A0.014%
2/11/2021Lazard Asset Management LLC2,645$68K0.0%N/A0.004%
2/11/2021Trexquant Investment LP13,425$0.35M0.0%-74.5%0.021%
2/11/2021Northern Trust Corp535,565$13.90M0.0%-3.1%0.825%
2/11/2021Barclays PLC46,074$1.20M0.0%-20.5%0.071%
2/11/2021Citigroup Inc.23,518$0.61M0.0%+211.7%0.036%
2/11/2021Asymmetry Capital Management L.P.348,408$9.05M4.1%+170.0%0.537%
2/11/2021Dynamic Technology Lab Private Ltd8,343$0.22M0.0%-49.9%0.013%
2/10/2021Rhumbline Advisers51,361$1.33M0.0%+11.1%0.079%
2/10/2021Panagora Asset Management Inc.144,787$3.76M0.0%-2.2%0.223%
2/10/2021Anfield Capital Management LLC8,041$0.21M0.1%N/A0.012%
2/9/2021Wells Fargo & Company MN108,285$2.81M0.0%+20.3%0.167%
2/9/2021Bank of New York Mellon Corp182,563$4.74M0.0%+11.6%0.281%
2/9/2021ProShare Advisors LLC9,338$0.24M0.0%N/A0.014%
2/9/2021Great Lakes Advisors LLC194,810$5.06M0.1%N/A0.300%
2/8/2021Vident Investment Advisory LLC55,334$1.44M0.1%+23.0%0.085%
2/8/2021State Board of Administration of Florida Retirement System13,500$0.35M0.0%+6.2%0.021%
2/8/2021New York State Common Retirement Fund38,200$0.99M0.0%+30.4%0.059%
2/5/2021IndexIQ Advisors LLC15,090$0.39M0.0%+11.5%0.023%
2/5/2021BlackRock Inc.3,255,091$84.50M0.0%+4.0%5.014%
2/5/2021Aperio Group LLC8,909$0.23M0.0%N/A0.014%
2/5/2021Swiss National Bank95,396$2.48M0.0%+13.8%0.147%
2/5/2021SG Americas Securities LLC11,869$0.31M0.0%-63.5%0.018%
2/4/2021State of Wisconsin Investment Board245,300$6.37M0.0%-1.2%0.378%
2/2/2021California Public Employees Retirement System93,575$2.43M0.0%-1.9%0.144%
2/2/2021First Trust Advisors LP48,950$1.27M0.0%N/A0.075%
2/1/2021Victory Capital Management Inc.1,132,562$29.40M0.0%-4.7%1.744%
2/1/2021Assenagon Asset Management S.A.41,674$1.08M0.0%-86.9%0.064%
1/28/2021Arizona State Retirement System12,235$0.32M0.0%+9.7%0.019%
1/28/2021Zurcher Kantonalbank Zurich Cantonalbank7,797$0.20M0.0%+146.9%0.012%
1/25/2021Nisa Investment Advisors LLC2,450$64K0.0%N/A0.004%
1/25/2021Strs Ohio18,800$0.49M0.0%+46.9%0.029%
1/22/2021Candriam Luxembourg S.C.A.409,006$10.62M0.1%-16.3%0.630%
1/20/2021Pacer Advisors Inc.2,079$54K0.0%+19.4%0.003%
12/14/2020Strs Ohio12,800$0.22M0.0%-3.8%0.020%
11/17/2020California State Teachers Retirement System63,790$1.09M0.0%+29.3%0.098%
11/16/2020Cubist Systematic Strategies LLC36,495$0.63M0.0%-47.0%0.056%
11/16/2020Point72 Asset Management L.P.194,001$3.33M0.0%N/A0.299%
11/16/2020AQR Capital Management LLC65,440$1.12M0.0%+12.5%0.101%
11/16/2020Squarepoint Ops LLC115,163$1.97M0.0%-27.9%0.177%
11/16/2020Engineers Gate Manager LP34,751$0.60M0.0%N/A0.054%
11/16/2020Alkeon Capital Management LLC714,845$12.25M0.0%+16.3%1.101%
11/13/2020Morgan Stanley28,826$0.49M0.0%-68.5%0.044%
11/13/2020Charles Schwab Investment Management Inc.282,973$4.85M0.0%+10.4%0.436%
11/13/2020UBS Asset Management Americas Inc.22,800$0.39M0.0%-26.0%0.035%
11/13/2020Virtus ETF Advisers LLC11,075$0.19M0.1%-12.1%0.017%
11/13/2020Great West Life Assurance Co. Can98,984$1.35M0.0%+5,791.9%0.152%
11/12/2020Connor Clark & Lunn Investment Management Ltd.86,014$1.47M0.0%N/A0.132%
11/12/2020JPMorgan Chase & Co.439,858$7.66M0.0%+7.0%0.678%
11/12/2020Arrowstreet Capital Limited Partnership183,389$3.14M0.0%+133.5%0.282%
11/12/2020Federated Hermes Inc.117,285$2.01M0.0%+124.6%0.181%
11/10/2020State Street Corp2,518,468$43.17M0.0%+58.6%3.880%
11/10/2020Bank Julius Baer & Co. Ltd Zurich25,949$0.45M0.0%+34.8%0.040%
11/9/2020SG Americas Securities LLC32,526$0.56M0.0%+121.8%0.050%
11/9/2020Caas Capital Management LP280,837$4.81M0.1%N/A0.433%
11/9/2020The Manufacturers Life Insurance Company23,852$0.41M0.0%+20.4%0.037%
11/9/2020Victory Capital Management Inc.1,188,559$20.37M0.0%+33.2%1.831%
11/9/2020State Board of Administration of Florida Retirement System12,710$0.22M0.0%+5.6%0.020%
11/6/2020BlackRock Inc.3,129,282$53.64M0.0%+18.6%4.821%
11/6/2020Trexquant Investment LP52,676$0.90M0.1%+79.5%0.081%
11/6/2020GSA Capital Partners LLP31,217$0.54M0.1%+231.5%0.048%
11/6/2020Aigen Investment Management LP12,516$0.22M0.0%N/A0.019%
11/6/2020Zurcher Kantonalbank Zurich Cantonalbank3,158$54K0.0%+118.7%0.005%
11/5/2020California Public Employees Retirement System95,375$1.64M0.0%+28.8%0.147%
11/5/2020Wells Fargo & Company MN89,998$1.54M0.0%+2.1%0.139%
11/4/2020American International Group Inc.25,205$0.43M0.0%+25.2%0.039%
11/2/2020White Pine Investment CO18,939$0.33M0.1%N/A0.029%
10/30/2020BNP Paribas Arbitrage SA10,936$0.19M0.0%+216.7%0.017%
10/27/2020Parallel Advisors LLC85,225$1.46M0.1%-1.9%0.131%
10/19/2020Candriam Luxembourg S.C.A.488,670$8.38M0.1%+119.2%0.753%
10/19/2020Pacer Advisors Inc.1,741$30K0.0%N/A0.003%
10/7/2020Assenagon Asset Management S.A.318,287$5.46M0.0%+117.8%0.490%
9/15/2020Two Sigma Advisers LP252,100$6.24M0.0%+239.8%0.388%
8/25/2020Nuveen Asset Management LLC281,427$6.96M0.0%+19.2%0.434%
8/20/2020Charles Schwab Investment Management Inc.256,253$6.34M0.0%+30.6%0.395%
8/17/2020AQR Capital Management LLC58,162$1.44M0.0%+123.9%0.090%
8/17/2020Great West Life Assurance Co. Can1,680$41K0.0%+292.5%0.003%
8/17/2020Sei Investments Co.11,938$0.30M0.0%N/A0.018%
8/14/2020Orbimed Advisors LLC220,350$5.45M0.1%N/A0.479%
8/14/2020Cubist Systematic Strategies LLC68,876$1.70M0.0%N/A0.150%
8/14/2020Point72 Hong Kong Ltd12,406$0.31M0.0%N/A0.027%
Data available starting January 2016

See Full Table
Arcus Biosciences logo
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab (AB154), its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; license agreements with Taiho Pharmaceutical Co., Ltd and Abmuno Therapeutics LLC; and strategic relationship with WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was founded in 2015 and is based in Hayward, California.
Read More

Today's Range

Now: $35.33
$32.47
$35.77

50 Day Range

MA: $35.71
$28.98
$41.39

52 Week Range

Now: $35.33
$9.85
$42.36

Volume

459,370 shs

Average Volume

539,651 shs

Market Capitalization

$2.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Who are the company insiders with the largest holdings of Arcus Biosciences?

Arcus Biosciences' top insider shareholders include:
  1. Gilead Sciences Inc (Major Shareholder)
  2. Robert C Goeltz II (CFO)
  3. William Grossman (Insider)
  4. Juan C Jaen (President)
  5. Kathryn E Falberg (Director)
  6. Terry J Rosen (CEO)

Who are the major institutional investors of Arcus Biosciences?

Arcus Biosciences' top institutional shareholders include:
  1. BlackRock Inc. — 5.01%
  2. Victory Capital Management Inc. — 1.74%
  3. Northern Trust Corp — 0.82%
  4. JPMorgan Chase & Co. — 0.77%
  5. Candriam Luxembourg S.C.A. — 0.63%
  6. Asymmetry Capital Management L.P. — 0.54%

Which major investors are selling Arcus Biosciences stock?

In the previous quarter, RCUS stock was sold by these institutional investors:
  1. Assenagon Asset Management S.A.
  2. Candriam Luxembourg S.C.A.
  3. Victory Capital Management Inc.
  4. Baker BROS. Advisors LP
  5. Trexquant Investment LP
  6. Credit Suisse AG
  7. Squarepoint Ops LLC
  8. Jane Street Group LLC

Which major investors are buying Arcus Biosciences stock?

During the previous quarter, RCUS stock was acquired by institutional investors including:
  1. Asymmetry Capital Management L.P.
  2. Great Lakes Advisors LLC
  3. BlackRock Inc.
  4. JPMorgan Chase & Co.
  5. First Trust Advisors LP
  6. Tudor Investment Corp Et Al
  7. Principal Financial Group Inc.
  8. Bank of New York Mellon Corp
During the previous year, these company insiders have bought Arcus Biosciences stock:
  1. Gilead Sciences Inc (Major Shareholder)
  2. Robert C Goeltz II (CFO)
  3. William Grossman (Insider)
  4. Juan C Jaen (President)
  5. Kathryn E Falberg (Director)
  6. Terry J Rosen (CEO)
Man Who Picked Apple Under $2 Issues NEW Urgent Buy
He picked Apple back in 2003… BEFORE shares skyrocketed almost 48,000%.

He picked Bitcoin when it was trading for just $428. Since then, it has exploded over 9,000%.

And now he's saying this will be the hottest investment of 2021.
Click here and get the ticker… no strings attached.
pixel